A Semaglutide Patch and an Amycretin Bet
Week Of June 27 - July 3, 2026
This week saw testing begin for a needle-free way to give semaglutide, as Terrestrial Bio dosed the first patients in a Phase 1 trial of a dissolving microneedle patch designed to match an injection. Novo Nordisk also began recruiting a roughly 900-site Phase 3 heart-failure trial for amycretin (zenagamtide) and opened a $50-a-month Medicare bridge for Wegovy.
🔥 THIS WEEK’S KEY DEVELOPMENTS
Novo Nordisk launches $50 monthly Medicare access program for Wegovy
Novo Nordisk announced that Wegovy® (semaglutide) injection and pill are now accessible to eligible Medicare beneficiaries with obesity through the Medicare GLP-1 Bridge program. This new pathway provides access for a $50 monthly copay and runs through the end of 2027. The company also stated that the Wegovy® pill has reached 3 million prescriptions since its launch in January 2026.
Press | Mechanism: GLP-1
Novo’s amycretin enters Phase 3 recruitment in heart failure, standing up a roughly 900-site global trial
Novo Nordisk’s amycretin (NNC0487-0111), its next-generation GLP-1/amylin dual agonist, moved its Phase 3 HF-POLARIS trial (NCT07567001) from not-yet-recruiting to recruiting this week, activating roughly 900 clinical sites across more than two dozen countries for a 5,610-patient study in people with obesity and heart failure. The scale signals Novo’s conviction in taking amycretin beyond weight loss into a hard cardiometabolic indication, the same heart-failure-with-obesity territory where semaglutide and tirzepatide have already shown benefit. It also mirrors Amgen, whose competing MariTide trial (MARITIME-HF, NCT07037459, roughly 5,000 patients) added dozens of sites the same week, putting two next-generation incretin programs into heart failure at once.
ClinicalTrials.gov: NCT07567001 (HF-POLARIS) | Mechanism: GLP-1 / amylin dual agonist
💡 TRIAL SPOTLIGHT
Educational spotlight selected by editors
Semaglutide Without the Needle: A Dissolving Microarray Patch Enters the Clinic
Terrestrial Bio (formerly Vaxess Technologies) dosed the first patients on July 1, 2026, in a Phase 1 trial (NCT07673900) evaluating VX-201, a needle-free microarray patch branded as Tacterra that delivers the established GLP-1 receptor agonist semaglutide. Conducted with the clinical research organization Celerion, the head-to-head study enrolls 62 healthy overweight or obese adults to compare standard subcutaneous injection against the patch, which uses a spring-loaded applicator to deposit dissolving microneedles epi-intradermally into the skin within five minutes. Because the drug molecule is already proven, the developmental risk centers on pharmacokinetics and skin tolerability, aiming to show that human exposure matches the bioavailability previously seen in preclinical minipig models.
A December 2025 human factors study indicated that 95 percent of participants preferred this room-temperature, self-applied system over standard injection pens, suggesting a potential adherence benefit for people who find injections uncomfortable or hard to sustain. Expected to complete its primary endpoint around February 2027, the trial reflects a broader strategic shift in the obesity market, where alternative delivery methods like patches, oral pills, and subcutaneous implants are becoming key battlegrounds for competitive differentiation ahead of eventual losses of exclusivity.
ClinicalTrials.gov: NCT07673900 (VX-201 semaglutide microarray patch vs subcutaneous)
🔬 MECHANISM EXPLAINED
Understanding the science behind the therapeutics
Getting a Peptide Through Skin: How Dissolving Microneedle Patches Deliver a GLP-1 (Example drugs: Semaglutide via VX-201)
With Terrestrial Bio bringing its VX-201 microarray patch into the clinic this week, the glucagon-like peptide-1 (GLP-1) delivery landscape is expanding to overcome a fundamental biological challenge. Peptides like semaglutide are large and water-loving (hydrophilic), meaning they cannot passively cross the skin’s outermost barrier known as the stratum corneum, which is the key distinction from the many over-the-counter “GLP-1 patches” sold online that are not drug products and do not deliver any peptide. To bypass that barrier, a microarray patch uses micron-scale needles that painlessly penetrate just past the stratum corneum into the epidermis and upper dermis, avoiding the deeper nerve endings and blood vessels that make conventional injections hurt. In the VX-201 design, a spring-loaded applicator seats the patch, after which the base dissolves within minutes to leave an epi-intradermal deposit of drug-loaded needle tips that then dissolve in the skin’s interstitial fluid. Because the peptide is released directly into well-perfused tissue with rich capillary and lymphatic networks, preclinical studies in Göttingen minipigs show semaglutide microarray patches reaching bioavailability comparable to subcutaneous injection, far above the roughly 1 percent bioavailability of oral pills that depend on absorption enhancers and strict fasting.
The appeal is real: room-temperature stability that removes the cold-chain requirement, no sharps waste, and fast self-application that could improve adherence. So are the constraints. Dose is limited by how much drug fits in the tiny tips, which suits potent, low-dose peptides but makes higher-dose regimens harder to formulate, and manufacturing dissolving arrays at commercial scale is nontrivial. Patches now join a crowded delivery menu alongside weekly injections, oral pills, and multi-month subcutaneous implants, and the race to crack peptide delivery runs deep across all of them: in February 2026 Novo Nordisk struck a partnership worth up to roughly 2.1 billion dollars with Vivtex, a startup from Robert Langer’s laboratory at the Massachusetts Institute of Technology, to make metabolic peptides orally absorbable.
🆕 NEWLY REGISTERED TRIALS (3 in last week)
PG-102(MG12) Phase II investigating a switch from dulaglutide in patients with type 2 diabetes mellitus (ProGen. Co., Ltd., n=60)
[Weight Loss/Efficacy]
Trials: NCT07677891 | Mechanism: GLP-1/GLP-2 dual agonist
CLARA Trial Phase 2 investigating the biological impact of GLP-1/GIP receptor agonists in patients with breast cancer (Universitaire Ziekenhuizen KU Leuven, n=168)
[New Indications]
Trials: NCT07676331 (CLARA) | Mechanism: Dual GLP-1/GIP agonist
Semaglutide microarray patch (VX-201) Phase 1 comparing epi-intradermal delivery to standard subcutaneous injection in healthy overweight and obese participants (Terrestrial Bio, n=62)
[Novel Delivery]
Trials: NCT07673900 | Mechanism: GLP-1 receptor agonist
This newsletter compiles publicly available information from press releases, news sources, and trial registries. Not investment advice.
Get in touch: Reply to this email, leave a comment on the post, or find me on X @GLP1observer. Explore the GLP-1 dashboard at glp1.bio1up.com, or browse the GLP-1 Field Guides for explainers on each mechanism class.